
Top insights from the Endpoints at ASCO McKesson leadership panel
Guided by our values, we are an impact-driven organization that improves care in every setting – one product, one partner, one patient at a time.
Through our core commitments, we are leveraging our scale for the greater good, such as serving the needs of our stakeholders, donating back to our communities, protecting our planet, working with policymakers, and more.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportOur businesses bring together leading technologies, innovative solutions and hands-on expertise to support the entire healthcare ecosystem.
We distribute pharmaceuticals and medical supplies to healthcare settings across North America, from pharmacies and hospitals to doctors’ offices and clinics.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
We provide research, insights, technologies and other support to help address challenges in cancer and specialty care.
We provide a suite of solutions designed to address access, affordability and adherence challenges by bridging the gaps between biopharma companies, pharmacies, providers, and payers to help patients get on and stay on their medications.
We offer solutions that enable employers, payers, health-plan brokers and government agencies to provide lower-cost options for prescription medications and therapies.
We help to ensure the financial wellbeing of pharmacies and health systems and support a stable work environment for their employees.
Every year, we publish updates to our commitments through our Impact Report.
Download Our Impact ReportLearn how McKesson's Clinical Research Services business supports clinical trials to advance medical knowledge and improve patient care.
Read time: 4 minutes
In today's ever-evolving healthcare field, innovative new therapies are turning once hard-to-treat diseases into manageable and even treatable conditions. At the center of these advancements are clinical trials, which have long served as the linchpin in the drug development process. Yet they also require a wide range of resources to be successful.
While the quest for groundbreaking medical discoveries continues, McKesson's Clinical Research Services (CRS) is pushing the boundaries of what's possible with initiatives aimed at simplifying clinical trial logistics and, ultimately, helping bring many of these promising new therapies to patients.
CRS offers clinical research support to many Phase I-III FDA-approved clinical trials for biopharma companies, contract research organizations, academic institutions, and site management organizations. The team provides customized inventory management, pharmacy and distribution solutions, and medication sourcing from manufacturers – all of which cater to the unique requirements of each study.
"Clinical trials are the backbone of medical progress and the key to unlocking breakthroughs that transform patient health,” says Tom Traylor, senior vice president of Pharmacy Dispensing and Automation at McKesson. “With a deep understanding of trial specifics and expert guidance to support the logistical complexities of the trial, we help facilitate the safe storage and delivery of potentially lifesaving and life-improving investigational therapies to clinical trial sites and, in some cases, directly to patients participating in clinical trials from home."
A clinical trial’s success is heavily contingent upon the proper handling and timely delivery of the investigational drug.
Recognizing the importance of preserving the safety and efficacy of these medications throughout the distribution process, CRS operates state-of-the-art facilities to properly store, dispense at the patient level or distribute bulk shipments to trial sites in all 50 U.S. states. These facilities operate with temperature-controlled storage areas that are closely monitored for drugs that must be kept at certain temperatures to remain viable. Prior to shipment, control checks are performed to help ensure the correct medications are delivered to the correct location and at the right time.
CRS has the ability to distribute the medication overnight to its destination, thus minimizing the time in transit and aiding in maintaining the integrity of the drug.
Today, the CRS team handles clinical trial logistics for numerous renowned oncology practices and research institutions across the U.S.
Among the many leaders in clinical trials that CRS works with is the Sarah Cannon Research Institute (SCRI), which conducts many community-based clinical trials.
For SCRI, a McKesson joint venture with HCA Healthcare, CRS plays a pivotal role in the availability of medications at SCRI's network of trial sites by delivering the products directly to them.
"In support of this joint venture, we operate a dedicated facility called the Investigational Products Center (IPC), which stores and dispenses investigational drugs and lab kits exclusively to SCRI sites in order to reduce their need for onsite storage," says Brian Richard, vice president of Clinical Research Operations. "We serve research sites within SCRI's network so that they can keep their focus on what's important – their patients."
A notable trend in healthcare today is the increased need for the availability of care closer to home. Traveling long distances to participate in clinical trials can be challenging – or even impossible – for many.
"A patient may learn of a clinical trial and get discouraged at the thought of traveling to a site every day, weekly or whatever the case might be," Richard says. "We don't want that to be a barrier to receiving potentially groundbreaking therapy."
With this in mind, CRS developed a direct-to-patient approach to support studies, if available, depending on trial specifics.
"We know every study is different," Richard says. "With our dispensing services, our team can provide an additional level of convenience to the patient by minimizing the need to travel to a facility for treatment.”
Ultimately, the CRS team is well-positioned to play distinct role in McKesson’s pursuit of advancing health outcomes.
“Patients are at the center of everything we do,” Traylor explains. “Our goal is to be a trusted partner and help pave the way for promising new therapies that could potentially improve the quality of life for countless individuals."
Top insights from the Endpoints at ASCO McKesson leadership panel
Enhancing patient access and engagement in clinical trials.
Learn how InspiroGene is helping deliver revolutionary cell and gene therapies to patients in need.
Insights from the 2025 CoverMyMeds Medication Access Report, From Barriers to Bridges
Learn about the crucial role Sarah Cannon Research Institute (SCRI) played in helping a patient overcome prostate cancer.
For two years in a row, McKesson has partnered with customers and industry partners to bring health education and awareness of resources to members of the Navajo community.
Learn more about RxOwnership, McKesson’s strategic consultants who help independent pharmacy owners navigate challenges, optimize operations and achieve financial health.
During the recent STAT @ ASH event in San Diego, panelists explored the role of community oncology in advancing precision medicine for cancer care.
Learn about McKesson’s new Cell and Gene Therapy (CGT) brand, InspiroGene, and the launch of a first-of-its-kind report about the CGT landscape and its future trajectory.
Milken Institute Future of Health Summit panelists address critical industry challenges and explore ways to futureproof the pharmaceutical supply chain.